Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Bernie Sanders calls for RFK Jr. to resign...
Top Senate Republican ready to go nuclear, ‘roll...
Altech Batteries LtdCERENERGY Battery 46.7M Euro German Grant...
Altech – CERENERGY Battery 46.7M Euro German Grant...
Locksley Resources LimitedStrengthens Leadership to Accelerate Growth Strategy
Heliostar Presents Second Quarter 2025 Financial Results
Apollo to Proceed with 5-for-1 Share Consolidation
Rhode Island’s ‘Taylor Swift Tax’ on vacation homes...
Former FBI Director Robert Mueller has Parkinson’s disease:...
Earthwise Advertising & Investor Awareness Campaign
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

by admin September 23, 2024
September 23, 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved the required response rate to support continued enrolment in the study. Six (6) patients have now recorded confirmed partial responses (PRs) out of 16 assessed at the four-month timepoint, indicating that the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is sufficiently active to support continuation of the trial.

HIGHLIGHTS

Six (6) patients in the Company’s ACCENT trial in pancreatic cancer have now achieved the required reduction in tumour size with no detection of new lesionsThe ACCENT trial can now proceed to recruit the next cohort of 24 patients, giving a total of 50 patients on studyThe ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients

The formal term ‘confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period.

A total of 50 patients are planned for the Phase 2a ACCENT trial. With the six (6) confirmed PRs now obtained, recruitment of the remaining 24 patients in the trial will begin at the existing open trial sites in Australia and South Korea. Recruitment of the second cohort of patients is expected to be completed by end of Q1 2025.

A detailed interim analysis of the Phase 2a trial data obtained to date will be reported in the coming weeks; however, key points are noted below:

Narmafotinib continues to be generally well tolerated by patients with no safety trends identified or dose reductions recorded to dateIn addition to 6 confirmed PRs, there have been 7 patients who have recorded stable disease over 2 or more months, including one patient whose stable disease has improved to achieve a partial response at their 4-month assessment

Amplia CEO and MD Dr Chris Burns commented: “Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial’

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Operations Update
next post
Nordic Nickel Limited (ASX: NNL) – Trading Halt

You may also like

US Capital Global Facilitates $50MM Financing to Accelerate...

June 6, 2025

Hempalta Corp. Announces Financial Results for Three Months...

March 4, 2025

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in...

December 11, 2024

Top 5 Canadian Mining Stocks This Week: Minsud...

February 22, 2025

NVIDIA Delivers Record Quarter as AI Demand Booms,...

August 29, 2025

Pan American Silver Gets Green Light for US$2.1...

August 26, 2025

Fortune Minerals Announces New Convertible Security Agreement With...

July 30, 2025

Top 5 Canadian Mining Stocks This Week: Cerrado...

October 19, 2024

Grant Williams: Market Turbulence Ahead, but Resource Space...

January 30, 2025

Tariff Fallout: GM’s Shift Cut in Oshawa Triggers...

May 6, 2025

Recent Posts

  • Bernie Sanders calls for RFK Jr. to resign as HHS secretary over vaccine policies: ‘Rally the American people’
  • Top Senate Republican ready to go nuclear, ‘roll over’ Democrats with rule change to confirm Trump nominees
  • Altech Batteries LtdCERENERGY Battery 46.7M Euro German Grant Approval
  • Altech – CERENERGY Battery 46.7M Euro German Grant Approval
  • Locksley Resources LimitedStrengthens Leadership to Accelerate Growth Strategy

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (903)
    • Investing (2,877)
    • Politics (3,527)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.